Takeda Delays EU Try For Key Diabetes Drug After U.S. Snag
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical is delaying by two years its plan to seek European Union approval of its SYR-322 (alogliptin) diabetes drug, citing a need to conduct another study. Takeda delayed the EU move after U.S. FDA said it needed more data for its approval of the drug. The delays are considered a setback for the drug maker, said to be relying on the drug as a successor to its biggest-selling Actos (pioglitazone), set to lose its patent protection in 2011. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.